These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 33772528)

  • 21. Serum transglutaminase 2 activity as a potential biomarker of disease severity and response to omalizumab in chronic spontaneous urticaria.
    Bae Y; Kang SH; Park JO; Park GH; Choi JH
    Allergol Int; 2020 Apr; 69(2):304-306. PubMed ID: 31767272
    [No Abstract]   [Full Text] [Related]  

  • 22. Antinuclear antibodies are common and linked to poor response to omalizumab treatment in patients with CSU.
    Ertaş R; Hawro T; Altrichter S; Özyurt K; Erol K; Ketenci Ertaş Ş; Maurer M
    Allergy; 2020 Feb; 75(2):468-470. PubMed ID: 31469912
    [No Abstract]   [Full Text] [Related]  

  • 23. Case Report: Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Crohn's Disease.
    Barni S; Giovannini M; Liccioli G; Sarti L; Gissi A; Lionetti P; Mori F
    Front Immunol; 2021; 12():635069. PubMed ID: 33737936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful treatment of four types of chronic urticaria with anti-IgE omalizumab in the same patient.
    Nettis E; Di Leo E; Calogiuri G; Foti C; Macchia L
    Ann Allergy Asthma Immunol; 2019 Mar; 122(3):336-337. PubMed ID: 30529714
    [No Abstract]   [Full Text] [Related]  

  • 25. Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience.
    Acar A; Gerceker Turk B; Ertam Sagduyu I; Ceylan C; Ozturk G; Unal I
    Cutan Ocul Toxicol; 2020 Sep; 39(3):249-253. PubMed ID: 32597235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of omalizumab on patient-reported outcomes in chronic idiopathic urticaria: Results from a randomized study (XTEND-CIU).
    Casale TB; Murphy TR; Holden M; Rajput Y; Yoo B; Bernstein JA
    J Allergy Clin Immunol Pract; 2019; 7(7):2487-2490.e1. PubMed ID: 31034999
    [No Abstract]   [Full Text] [Related]  

  • 27. Are currently available biomarkers useful to discriminate CSU patients not controlled by low dose omalizumab maintenance therapy?
    Asero R
    Eur Ann Allergy Clin Immunol; 2020 Nov; 52(6):268-270. PubMed ID: 32191021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time-Dependent Effects in Chronic Urticaria: A Time-Series Perspective of Omalizumab Treatment.
    Tagka A; Lambrou GI; Makris M; Nakou E; Nicolaidou E; Chatziioannou A; Katsarou A
    Endocr Metab Immune Disord Drug Targets; 2020; 20(10):1726-1739. PubMed ID: 32167432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hematologic parameters as biomarkers for antihistamine and omalizumab resistance in chronic spontaneous urticaria.
    Magen E; Waitman DA; Kahan NR
    Allergy Asthma Proc; 2021 Jan; 42(1):e17-e24. PubMed ID: 33404397
    [No Abstract]   [Full Text] [Related]  

  • 30. Chronic Urticaria.
    Hsu JI; Hsu S
    Skinmed; 2022; 20(5):364-366. PubMed ID: 36314703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic Urticaria.
    Hsu JI; Hsu S
    Skinmed; 2022; 20(4):364-366. PubMed ID: 36314621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How does omalizumab affect the immunoinflammatory response in patients with chronic spontaneous urticaria?
    Önder S; Ozturk M
    Cutan Ocul Toxicol; 2020 Mar; 39(1):31-35. PubMed ID: 31642341
    [No Abstract]   [Full Text] [Related]  

  • 33. Atopic status and thyroid autoimmunity do not predict omalizumab response in severe chronic spontaneous urticaria patients.
    Asero S
    Eur Ann Allergy Clin Immunol; 2024 May; 56(3):141-143. PubMed ID: 36786337
    [No Abstract]   [Full Text] [Related]  

  • 34. Therapeutic Strategy According to Differences in Response to Omalizumab in Patients With Chronic Spontaneous Urticaria.
    Giménez Arnau AM; Valero Santiago A; Bartra Tomás J; Jáuregui Presa I; Labrador Horrillo M; Miquel Miquel FJ; Ortiz de Frutos J; Sastre J; Silvestre Salvador JF; Ferrer Puga M
    J Investig Allergol Clin Immunol; 2019; 29(5):338-348. PubMed ID: 30222111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Crucial Role of IgE as a Predictor of Treatment Response to Omalizumab in Chronic Spontaneous Urticaria.
    Maurer M; Kolkhir P; Moñino-Romero S; Metz M
    J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2390-2391. PubMed ID: 37364668
    [No Abstract]   [Full Text] [Related]  

  • 36. Does synthetic pharmacotherapy still have a place in treating chronic spontaneous urticaria?
    Thiede RM; Fazel M; MacDonald KM; Abraham I
    Expert Opin Pharmacother; 2022 Oct; 23(14):1563-1567. PubMed ID: 36173375
    [No Abstract]   [Full Text] [Related]  

  • 37. Omalizumab serum levels predict treatment outcomes in patients with chronic spontaneous urticaria: A three-month prospective study.
    Ghazanfar MN; Bartko EA; Arildsen NS; Poulsen LK; Jensen BM; Enevold C; Holm JG; Woetmann A; Ødum N; Thomsen SF
    Clin Exp Allergy; 2022 May; 52(5):715-718. PubMed ID: 35278253
    [No Abstract]   [Full Text] [Related]  

  • 38. Selective IgE Deficiency Predicts Poor or No Response of Chronic Spontaneous Urticaria to Omalizumab.
    Picado C; Mascaró JJ; Vlagea A; Pascal M; Muñoz-Cano R; Bartra J
    J Investig Allergol Clin Immunol; 2022 Dec; 32(6):504-506. PubMed ID: 35225792
    [No Abstract]   [Full Text] [Related]  

  • 39. Real-life clinical practice with omalizumab in 134 patients with refractory chronic spontaneous urticaria: a single-center experience.
    Akdaş E; Adışen E; Öztaş MO; Aksakal AB; İlter N; Gülekon A
    An Bras Dermatol; 2023; 98(2):240-242. PubMed ID: 36567165
    [No Abstract]   [Full Text] [Related]  

  • 40. Concurrent use of omalizumab and dupilumab in a 47-year-old woman with chronic spontaneous urticaria and atopic dermatitis.
    Holm JG; Sørensen JA; Thomsen SF
    Int J Dermatol; 2022 May; 61(5):e173-e174. PubMed ID: 34813086
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.